Summary. This paper examines the history of orphan drug policy, from the emergence of 'orphans' in the American pharmaceutical market in the 1960s, through the debates and agitations that resulted in the passage of the US Orphan Drug Act of 1983, to attempts in the 1990s to prevent abuse of that Act and restore its original intentions. Although an increased number of drugs for rare diseases have since been developed and marketed, the extremely high price of some such drugs is considered a major public health issue internationally. The present paper traces the origins of this issue to the market-based approach to resolving the problem of orphan drugs embodied in the 1983 Act. The paper also makes visible an alternative trajectory that existed for a while in the United Kingdom but was eventually abandoned in order to help the biotechnology industry grow in the context of an increasingly integrated European drug market.
Introduction
This paper examines the history of orphan drug policy, especially in relation to the US Orphan Drug Act of 1983. The Act is often considered 'one of the most successful pieces of health related legislation passed in the United States'.
1 Its author, Representative
The impact of the Act is most commonly measured by the number of new treatments for rare diseases developed after its passage. Whereas only 10 drugs for such diseases had been approved by the US Food and Drug Administration (FDA) in the decade before 1983, by 2010, the agency had approved more than 350. 4 Orphan products, which barely existed before the 1980s, now account for about a third of all newly-approved drugs and biologics. 5 The legislation has also served as a model for law or policy internationally, inspiring similar enactments in the 1990s in Singapore, Japan, Australia and Europe. Some scholars view the legislation as creating a new 'field' or 'agora', in which multiple stakeholders with a shared interest in developing orphan drugs interact and cooperate-a development they view as a major achievement. 6 The empowerment of patients living with rare diseases is also commonly cited by health care professionals working in the field of rare diseases and others as a major achievement of the Orphan Drug Act, which patient advocacy was crucial in passing. 7 The impact of the Act on the lives of patients and their families has been expressed, both by individuals who took part in its passage and those who studied it retrospectively, by the idea of 'hope'. According to Waxman, orphan drugs were once a story of hopelessness. 8 However, over the last 20 years or so, patient organisations have actively and influentially interacted with physicians and researchers, in their search for curative and ameliorative interventions. Although individuals who played key roles in the development and passage of the Act as well as scholars writing on the topic have emphasised its benefits-the ways it shifted, in the words of sociologist Carlos Novas, the 'conduct of firms, industry, regulatory agencies in directions considered socially and economically desirable'-health economists and health policy analysts have increasingly voiced concerns about the prohibitive cost of some orphan drugs. 10 Although in the 1960s, drugs for rare diseases were 'orphaned' due to their lack of profitability, financial and other incentives to their development included in the Act and its modifications resulted in their becoming profitable by the beginning of the 1990s, with some treatments now prohibitively expensive. While
Waxman once said that with the Orphan Drug Act 'we have reordered the economics of pharmaceuticals to make the market work', the persistent challenge of making drugs for rare diseases available for patients indicates that the orphan drug market has yet to be made to work as well for them as is commonly assumed. 11 The aim of this paper, which is based on research in primary and secondary sources, including the records of Congressional hearings, and on a series of interviews with key individuals, is primarily to elucidate the historical contingency of the market-oriented approach to solving the problems of orphan drugs, and demonstrate the ways it was shaped by concerns other than addressing rare diseases and saving lives of those affected. Historical accounts of the Orphan Drug Act, whether related by those who played key roles in the political negotiations leading to its enactment or by others, have tended to present its market-based approach not as a choice but a necessity, reflecting the shared interest of various stakeholders. However, taking into account the entire span of orphan drug law and policy, this paper shows that adoption of a market-based approach to drugs for rare disorders was not a foregone conclusion, and it instead argues that the existence of alternative pathways is obscured when historical accounts focus too narrowly on the discussions that occurred at the beginning of the 1980s.
Orphaned in Drug Regulation Reform
The idea of some drugs being 'orphaned' emerged in the United States when pharmaceutical regulation in that country was undergoing major change after the passage of the 1962 Kefauver-Harris Amendments to the Food, Drug and Cosmetic Act. The bill was originally introduced by Senator Estes Kefauver (D-TN) to increase government control over the pharmaceutical industry and to reduce the price of prescription drugs. 12 Kefauver's original bill did not find sufficient support in Senate, but as a consequence of the thalidomide tragedy, a significantly revised version of the bill, emphasising the need to ensure the safety and efficacy of drugs, passed on both floors of Congress in October 1962. Although most of the provisions of the original bill that aimed to increase price competition in the pharmaceutical market had been removed, the Amendments demanded a rigorous but costly approach to clinical trials, authorising the FDA as the responsible government agency to oversee the process of drug development-the 'gatekeeper' of the US pharmaceutical market. 13 Weighing the risk of approving unsafe drugs against that of causing delay in approving life-saving drugs, the FDA decided to emphasise pre-market evaluation in its drug 17 While he suggested the regulations might need to be revised, no action followed.
It was also at this conference that Harry C. Shirkey, then chairman of the Committee on Drug Dosage of the American Academy of Pediatrics, first used the word 'orphan' in relation to drugs. He spoke of 'pharmaceutical orphans' in expressing his concern about an increasing number of drugs that were approved for use in adults, but not in infants and children, leaving children who might benefit from those drugs with fewer therapeutic options. 18 Shirkey later reasoned that this was due to the small sales potential of such drugs, relative to the cost of obtaining separate FDA approval for paediatric use. 19 Five years later, George P. Provost, an editor of the American Journal of Hospital Pharmacy, invoked the idea of 'orphans' to describe substances that were held in hospital pharmacies but not approved for clinical use, despite having been used in preparing medicines before the 1962 Amendments. 20 Like Shirkey, Provost suspected that the reason the producers did not seek approval was insufficient profitability. Shirkey and Provost both observed that in the past pharmaceutical companies had supplied some drugs at a financial loss as a service to the public-so-called 'public service drugs' or 'service drugs'. Assuming that it was the increased cost of obtaining marketing approval that jeopardised this practice, they argued that doctors and pharmacists should do more to help companies secure approval by collecting relevant information about unprofitable drugs. The idea of 'orphan' was thus first invoked by medical professionals to point out some noticeable impacts of the Kefauver-Harris Amendments, in particular the abandonment of unprofitable drugs by pharmaceutical companies. However, neither the word nor the concern with unprofitable drugs assumed wider currency at that time. Rather, for much of the 1970s, debates about the consequences of drug regulation reform revolved around the concept of 'drug lag'. Introduced by clinical pharmacologists William M. Wardell and Louis Lasagna, the drug lag debate focused concerns that effective new drugs were reaching the market more slowly in the US market than elsewhere.
21
Unprofitable drugs were occasionally considered in this context as extreme instances of drug lag, which could only be addressed through 'the social responsibility of the industry'. 22 The FDA also paid passing attention to what it called 'drugs of limited commercial value' in 1975. Chaired by Marion J. Finkel, then associate director for new drug evaluation at the FDA Bureau of Drugs, the committee contemplated possible incentives to encourage pharmaceutical companies to produce such drugs, but concluded that the reasons they were neglected were too diverse to permit meaningful recommendations.
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In effect, they were 'orphaned', not just by their manufacturers, but also by those considering drug regulation reform in the United States for much of the 1970s.
In the Hands of the Nation at Large
A similar problem emerged in the United Kingdom in the mid-1970s. There, however, the problem was addressed very differently from the approach in the United States. As in the USA, the British drug regulation system had undergone considerable change after the thalidomide tragedy. 24 Initially, a voluntary licensing system was introduced, and the illustrative of 'an intriguing and important defect' in Britain's drug production system.
33
The magazine was subsequently able to report that a solution had been found for Walshe's case. 34 In 1978, the UK Department of Health and Social Services (DHSS) obtained a Clinical Trials Certificate for trien, and the DHSS and the Laboratory of the Government Chemist began collaborating with a pharmaceutical manufacturer K&K-Greeff Chemicals to devise an effective production method. 35 The company started supplying the chemical to Walshe and others on the Clinical Trials Certificate in the same year. In this instance at least, the problem of drugs for rare diseases was resolved through cooperation between the British government and a local pharmaceutical manufacturer.
Increased Visibility of Patients
Meanwhile, in the United States, members of Congress were becoming aware of pharmaceutical companies' reluctance to develop drugs of limited commercial value, thanks in part to the effort of affected patients. 36 An early such instance was the Congressional 
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Interagency Task Force, Report, 13.
Orphans in the Marketapproach taken in Britain, however, the Task Force considered that the role of the government should 'be largely catalytic, managerial and supportive, with limited monetary or credit aid'. 42 The report acknowledged the past supply of service drugs by the pharmaceutical industry, suggesting that it was evidence of the industry's willingness and capacity to develop such drugs. 43 Convinced that the increased cost of obtaining FDA approval was the main factor deterring the industry from producing service drugs, the Task Force recommended a programme of financial support for clinical trials, which recipients would have to repay once their drugs reached the market. A new FDA advisory board should also be set up 'to encourage voluntary industry action as a matter of public interest and . . . accord appropriate recognition to firms which participate on the basis of humanitarian concern'. 44 The Task Force was particularly firm on the point that the essential conditions of safety and efficacy for drug approval-developed after the 1962 Kefauver-Harris Amendments-should not be compromised. In contrast to the British government's response to Walshe's trien problem, the FDA's approach was thus to provide financial and organisational support to pharmaceutical companies to offset the costs of securing marketing approval, and to encourage their voluntary commitment to produce more service drugs. Critics doubted whether this would be sufficient, however. Lasagna, for instance, observed that the FDA had never done anything to cut the costs of drug production, and argued that 'orphanization' of potentially useful but unprofitable drugs would likely persist, because their development was 'blocked through lack of interest on the part of the people and institutions whose commitment is necessary'-not only pharmaceutical companies but also the FDA. 
Orphan Drugs as Cases of Market Failure
The Orphan Drug Act did not simply enact Holtzman's original proposals, however. Rather, the Congressional deliberations that took place over the various bills led to a profound shift in how the orphan drug problem was conceived. Holtzman's bill, like the FDA Task Force from which it drew inspiration, saw the problem as one of ensuring that existing drugs were made available to patients. At the first hearing on Holtzman's bill, Finkel for the FDA accordingly recommended that government support should 'be provided only for drugs for which some evidence of probable safety and effectiveness already existed'-a criterion that applied to both the myoclonus and Tourette syndrome cases.
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Dobkin echoed this view. Speaking from her own experience with L-5HTP, she argued that 'the worst thing that can happen to a person is to hold a treatment in his hand, see the miracles it can bring, and then have it pulled away. ' Meyers' statement was based on her communication with other patient groups, whom she had contacted to see if they had faced similar problems to Tourette patients. 55 Many confirmed that they did-but some went further. Meyers and Dobkin were concerned that beneficial treatments had been taken away from them-'the worst thing' that Dobkin described. But some patients suffered from conditions for which no such effective treatment had ever even been developed-and these patients feared that the pharmaceutical industry's lack of interest in rare diseases meant they never would be. In effect, these patients indicated that the scope of the orphan drug problem needed to be expanded, to include not just the problem of securing access to existing but unapproved drugs, to the larger question of how to promote the development of new drugs for rare conditions. Waxman was sympathetic to this future-oriented view of the problem, and in opening the second hearing on Holtzman's bill, he spoke of 'victims of orphan diseases' in reference to patients of Tourette syndrome, Huntington's disease, amyotrophic lateral sclerosis and spina bifida, whose medical needs were ignored by drug manufactures because of the low number of patients affected.
56 Subsequently, when Waxman brought his own bill forward in place of Holtzman's, he included measures that were intended not just to ease the way to approval of existing drugs for rare conditions-for instance proposing that a single well-controlled clinical trial, backed up by post-marketing surveillance, should suffice for FDA approval-but also recommending substantial incentives for companies that brought such drugs, both pre-existing and novel, to market. 57 This included offering tax credits in proportion to the cost of clinical testing of designated orphan drugs, and granting seven-year exclusive marketing rights if the drug were not patent- 
Entangled with the Drug Regulation Reform Debate
Waxman's strategy was in effect to represent the orphan drug problem as one of market failure, attributable to the peculiarly small market for such drugs, and to be addressed by introducing market incentives aimed specifically at such products. 59 However, his efforts to demarcate the market of orphan drugs from the rest of the US pharmaceutical market initially met with considerable opposition from the pharmaceutical industry. Through the 1970s, the pharmaceutical industry had repeatedly challenged strict FDA regulations by pointing to the problem of 'drug lag', while occasionally citing the problem of drugs for rare conditions as a special case of this larger regulatory problem. 60 After the Quincy M.D. episode increased the public profile of the orphan drug problem, however, pharmaceutical companies began to realise that this might provide an opportunity to draw wider attention to their own concerns. Contrary to Waxman's understanding of the issue, therefore, their strategy turned on representing orphan drugs, not as a circumscribed problem of market failure, but as epitomising a wider problem of excessive FDA regulation on new drugs.
61
No one from the industry had attended to testify at the first hearing on Holtzman's bill. Following the Quincy M.D. broadcast, however, Lewis A. Engman, then president of the PMA, along with a few others from the industry, decided to testify at the second hearing in March 1981. Engman explained that the industry had in the past addressed issues of rare diseases by its supply of service drugs, and proposed that the PMA should continue to work to that end by establishing a Commission on Drugs for Rare Diseases, which would act as an information clearinghouse. However, he insisted that what was really needed was not new legislation but improvement in and speeding up of the drug approval process-not just for orphan drugs but for all drugs.
62 David E. Collins, then president of McNeil Pharmaceutical, supported Engman's argument, stating explicitly that 'the orphan drug problem is a significant manifestation of a broader problem relating to drug discovery, development and approval ' . 63 Several members of Congress also gave them their support: for example, Representative James H. Scheuer (D-NY) used the phrase 'regulatory overkill' to make the same point.
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The industry pursued the same line at the 1982 hearing on Waxman's bill. Peter Barton Hutt, former chief counsel of the FDA but now representing the PMA, again opposed any legislative action aiming specifically at orphan drugs. He first asserted the industry's commitment to solving the problem by noting its creation of the Commission on Drugs for Rare Diseases earlier that year. He then stated:
In our view there is no statutory inhibition to the development of orphan drugs. Rather the problem seems to be in how the law is implemented during the investigational new drug and new drug application review process. . . . It is an ' The pharmaceutical industry's priority was thus to challenge the conventions of FDA regulation in general, while resisting any measures aimed specifically at orphan drugs. Their views were shared by some within the administration itself. Thus where Waxman's bill proposed to expedite approval of orphan drugs by shifting the regulatory onus from premarket testing to post-marketing surveillance, Edward Brandt Jr., then associate secretary of health at the DHHS, argued that this measure was unnecessary because the FDA already had discretion to give patients faster access to drugs-whether orphan or nonorphan-as INDs on a compassionate basis. 66 Meanwhile, the FDA continued to defend its existing regulatory standards, while supporting the idea that special measures should be introduced to tackle the particular problem of orphan drugs. At the second hearing on Holtzman's bill, for instance, J. Richard Crout, then director of the FDA Bureau of Drugs, reiterated the view that the unmet needs of rare-disease patients represented a failure of the drug market rather than of drug regulation, and ended by reasserting the agency's policy of applying the same standards of safety and efficacy to both orphan and non-orphan drugs.
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Entangled as they now were in the wider political debate on drug regulation reform and the adequacy of the FDA's approach to regulating the pharmaceutical market, Waxman's legislative attempt might not have succeeded had he not received support from two other sources. The first of these was the emerging alliance of rare-disease patients and medical researchers. At the hearing on Waxman's bill, Jess G. Thoene of the University of Michigan, who was at that time running a clinical trial of a chemical component cysteamine in patients with a rare inborn error of metabolism called cystinosis, was impressed by Guthrie's testimony and invoked it in his own. 68 After the hearing, Guthrie said to him 'we are in this together, we cannot let this momentum slide, this is a major issue, let's work together'. The second, more unexpected source of support came from generic drug manufacturers. The hearing on Waxman's bill was happening at the same time as the growing generic drug industry was engaged in its own negotiations over the stringency of FDA regulations. 72 Founded at the beginning of the 1980s, the new Generic Pharmaceutical Industry Association (GPIA) was trying to secure an 'abbreviated new drug application', requiring only proof of bioequivalence rather than full-scale clinical trials for generic versions of drugs, which had previously received FDA approval and were now out of patent. 73 The FDA had already made this pathway available for generic versions of drugs approved before 1962, and negotiations now focused on more recently approved medicines. The GPIA was working with several legislators, including Waxman, on this issue.
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Soon after the hearing on Waxman's orphan drug bill, GPIA president William F. Haddad realised that one of the reasons why some drugs became orphaned was because they were not patent protected, so pharmaceutical companies were reluctant to invest in them. But off-patent drugs were precisely the territory that the emerging generic sector was trying to claim for itself, while the opportunity to address the orphan drug problem promised favourable publicity for the sector. The GPIA promptly set up the Institute for Orphan Drugs to encourage generic firms to seize this opportunity.
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The GPIA's swift action threatened to outflank the PMA, which was itself fighting for legislation to extend drug patents and so minimise competition from generic manufacturers. Faced with a potential public relations coup, the PMA capitulated and gave its support to Waxman's bill. 76 By doing so, the pharmaceutical companies also in effect conceded Waxman's construal of orphan drugs as cases of market failure, deserving distinctive arrangements from the rest of the drug market. As a result, they were no longer able to claim that orphan drugs were just extreme instances of a wider 'drug lag' problem. Meanwhile, having secured support from both consumers and potential suppliers of orphan drugs, Waxman's bill passed the House of Representatives with minor amendments, and the Orphan Drug Act was finally signed into law by US President Ronald Reagan in January 1983.
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The Machinery of Orphan Drugs
The 1983 Orphan Drug Act retained the provisions for seven-year exclusive marketing rights and tax credits-though reduced now to equal to 50 per cent of the cost of clinical The most significant adjustment made was to define 'rare diseases' in a way that clarified the boundary of the orphan drug market. The original Act had specified that in order to qualify for orphan drug designation, the manufacturer needed to set out the 'facts and circumstances' that rendered that drug unprofitable. 83 However, the FDA found it impossible to determine if a drug was eligible for orphan drug designation because the price of the product and the cost of its development-hence the prospect of making a profit or lack thereof-were not included in the information its sponsor conventionally submitted to the agency. 84 Finkel, in her new capacity as the first director of the FDA Office of Orphan Products Development (OOPD), had been aware of this issue and argued at the 1982 conference in Ann Arbor that it would be necessary to define the upper limits of profitability. 85 She suggested that a way to resolve this issue might be to specify 'the number of potential users of a drug'; she proposed 'an incidence of 0.05%'-that is, a prevalence of 100,000 patients in the United States-as a reasonable line to draw. 86 The figure was put to representatives of the industry and consumers at a meeting which Meyers attended as chair of NORD's Government and Industry Liaison Committee. During a break, Meyers took Finkel to the ladies' room-they were the only female attendees-and recommended that the figure be raised to 200,000 since a
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The clause was not favoured by the pharmaceutical industry because it felt that stating that only a single clinical trial would be required for orphan drugs could indicate that two trials were necessary for other drugs. Asbury, Orphan Drugs, 161-2. threshold of 100,000 would preclude at least three diseases that she knew of-Tourette syndrome, multiple sclerosis and narcolepsy. 87 The figure of 200,000 was duly adopted as the legal definition of a rare disease in the 1984 Amendments to the Orphan Drug Act.
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Further amendments to the Act were made in 1985. 89 These included expanding eligibility for seven-year market exclusivity to cover patentable as well as non-patentable drugs. At the House Oversight Hearing on the Act held prior to the amendments, the FDA had reported that a number of products had been submitted for orphan drug designation with patents which were due to expire before or soon after obtaining of FDA approval. 90 Such products were not currently covered by the Act. In order to incentivise development of such products by companies and to prevent the situation where the government had to take on the responsibility for their development, the condition that eligible substances be unpatented was struck out. 91 The amendments also established the National Commission on Orphan Diseases (NCOD) with the mandate of assessing activities relating to rare diseases undertaken by government agencies-including the NIH and the FDA-as well as those at private organisations. 92 The NCOD was directed by a former OOPD officer Stephen C. Groft and chaired by the Michigan researcher Jess G. Thoene. Its members also included Van Woert and Meyers, as well as Marlene E. Haffner, who had assumed directorship at the OOPD after Finkel left the FDA.
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Despite these adjustments, problems persisted with the working of the Act. Many of the drugs taken forward immediately after passage of the Act were ones for which prior knowledge of their safety and efficacy existed. But Waxman and others were worried that sufficient incentives were not yet in place to stimulate research into new drugs for rare diseases. 94 In the words of Van Woert, 'the machinery is now in place to develop known orphan drugs' but 'other approaches to stimulate and facilitate preclinical and early clinical research' were needed for its real success. 95 These worries were borne out by an NCOD report of 1989 which revealed that of the $1.3 billion that the US government spent on rare disease research in 1987, more than half was spent on approximately 200 rare forms of cancer-mostly studied at the National Cancer Institute-with about $640 million left for the other 4,800 rare diseases. 96 The report also revealed that many academic investigators believed that getting funding for research on rare diseases was harder to secure than for similar studies on more common diseases. 
Birth of Billion-dollar Orphans
By the late 1980s, concerns were being expressed that the market incentives provided under the 1983 Orphan Drug Act and its later amendments were not just encouraging the manufacture of otherwise unprofitable drugs, but were open to 'abuse', with some companies making 'exorbitant profits' from designated orphan drugs. 104 Consequently, Congress decided to investigate these concerns, and to evaluate the sustainability of the market-based approach to the orphan drug problem embodied in the Act.
In February 1990, a hearing was held before the House Subcommittee on Health and the Environment, at which three drugs were examined. Two of these were products of the new biotechnology industry: recombinant human growth hormone (r-HGH), marketed independently by Genentech and Eli Lilly, and approved for treatment of children with growth failure; and Amgen's recombinant erythropoietin (r-EPO), used to treat anaemia associated with chronic renal failure. 105 The third, aerosol pentamidine, was a conventional drug produced by Lyphomed to treat a type of pneumonia common to AIDS patients. Not only were these drugs expensive; there also existed companies interested in producing competitive products but prevented from doing so by the marketexclusivity clause of the Orphan Drug Act. At the hearing, Meyers argued that r-HGH was a clear case of abuse, since it would have been developed even without the incentives in the Act. 106 Aerosol pentamidine and r-EPO presented slightly different issues. Aerosol pentamidine was designated an orphan drug at a time when few AIDS patients had been identified. With the growth of the epidemic and hence the potential market, other companies wished to develop cheaper versions of the same drug, but the market exclusivity provisions of the Act prevented such competition. In the case of r-EPO, orphan drug status was granted on grounds of the rarity of the particular condition specified by its sponsor, despite knowledge that the drug could also be useful for a number of other indications-an approach that Gabriel Schmergel, then president of a competitor company The Genetic Institute, criticised as 'salami slicing'. 110 Consumers were alarmed at the high price of these drugs, but warned that any solution had to be devised in such a way that companies remained interested in developing orphan drugs. At the hearing, several approaches were considered. One-the idea of allowing 'shared exclusivity' to replace market monopoly with oligopolistic competition-was rejected because it would render the market-exclusivity provision of the Orphan Drug Act practically meaningless. Another was to control the price by setting an upper limit on the sales that a company could accrue from a drug before its orphan drug designation was rescinded, but this too was rejected: the logic of the market-based approach was to offer incentives in the form of potential profits, while it would be politically problematic to intervene in pricing decisions. Ironically labelling the drugs discussed at the hearing 'billion-dollar orphans', one reporter concluded that there was little prospect of a 'miracle cure' that would make both suppliers and consumers of orphan drugs happy. 111 in April 1991 and sold by Genzyme for treatment of Gaucher's disease; its estimated sales for the first 10 months were $120 million. At the hearing, Meyers again argued that the Act was not intended to help companies developing blockbuster products but to address cases of market failure.
114 Some rare diseases organisations disagreed, however.
Robert Dresing, then president of the Cystic Fibrosis Foundation, argued that rare-disease patients needed 'the power and force of the high technology and the sophistication that only the pharmaceutical and biotech industries could supply', insisting that the Act was serving its purpose. 115 Strong dissent was also expressed by Senator Orrin G. Hatch (R-UT), for whom the Orphan Drug Act was 'a success story'. 116 In his view, the amendments bill was 'a perfect example of a misguided effort to fix a law that isn't broken'. 117 Hatch also emphasised the importance of the Act to the still nascent biotechnology industry. 118 His argument was endorsed by Henri A. Termeer, then chief executive officer of Genzyme, who stated that for young biotechnology firms, like his, 'the orphan area is extremely important and extremely attractive'. 119 The bill died in Congress without a vote, and no cure was found for the Orphan Drug Act. Meanwhile, biotechnology companies continued to benefit. In 1994, Genzyme introduced a recombinant version of alglucerase, selling it at the same price as the earlier product while significantly reducing production costs. The case made clear that even 'true orphans' can be profitable, provided high enough prices could be extracted from consumers. 120 Thus, while it was evident that some companies made large profits from orphan drugs, Congressional deliberations in the 1990s left the market-based approach intact. As a result, 'billion-dollar orphans' multiplied and became increasingly widely accepted. Orphan drugs were no longer 'drugs of limited commercial value' but attractive business opportunities, while patients with rare diseases were no longer 'victims' of orphan diseases but 'consumers' in the potentially lucrative orphan drug market.
Discussion
The Orphan Drug Act of 1983 is commonly recognised as an important piece of legislation that for the first time addressed issues of rare diseases and conditions, which had long been neglected in the drug market. The idea of 'hope'-used by Waxman and others to justify their legislative efforts and sometimes echoed in scholarly 114 commentaries-emphasises the positive impact of the Act on the lives of those affected.
121 From being 'without hope', those affected by rare diseases now have reason to hope that drugs will be developed-a change that is also evident in their transformation from 'victims' of orphan diseases to 'consumers' of orphan products. 122 However, as Christine Hayes of the Huntington's Disease Society of America said in 1992, 'hope is no good if a drug is developed and our folks cannot afford it'. 123 The ongoing discussion about the extremely high price of some orphan drugs suggests that for some people living with rare diseases, the hope they have been given may turn out to be a false one. This paper has endeavoured to unravel this conundrum through social historical analysis. It has characterised the orphan drug policy developed in the United States as marketbased, in that it sought to solve the problem of orphan drug development by creating market incentives to encourage pharmaceutical companies and biotechnology firms to invest in producing new drugs, while avoiding interference in the pharmaceutical market more generally. This approach stands in contrast to the one initially taken in the United Kingdom, which also sought to mobilise industry, but through direct government involvement.
The market-based approach came to dominate in the United States in part because the FDA adhered to its policy on the 'risk versus risk' dilemma in drug regulation, insisting that pre-marketing evaluation should apply equally to orphan and non-orphan drugs.
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While Waxman's bill initially included a clause to place greater emphasis on post-marketing surveillance as part of its special arrangements for orphan drugs, it was removed before the Act was signed into law. In part, too, the decision to extend the seven-year market exclusivity provision to patentable drugs reflected the conviction that the FDAbeing the gatekeeper of the US drug market-should make minimal interventions in drug development. The market-based approach to the orphan drug problem thus reflected a peculiarly American understanding of the regulatory role of the FDA at that time, just as the UK approach reflected the more cooperative regulatory culture that existed in Britain.
To an extent, other countries came to regard the US approach to the orphan drug problem as a successful model, adopting aspects of a market-based approach into their own policies in the 1990s, in part because they saw it as effective in assisting the growth of the nascent biotechnology industry. The interaction between biotechnological innovation and orphan drug provision deserves further research. By the late 1980s, biotechnology startups were benefiting from the Orphan Drug Act, not least because securing orphan drug designation for their still-in-development products served as a milestone in their progress-signalling the promise of future profits-for their investors. 125 
